197 related articles for article (PubMed ID: 28389504)
1. Circulating tumor cells and miRNAs as prognostic markers in neuroendocrine neoplasms.
Zatelli MC; Grossrubatscher EM; Guadagno E; Sciammarella C; Faggiano A; Colao A
Endocr Relat Cancer; 2017 Jun; 24(6):R223-R237. PubMed ID: 28389504
[TBL] [Abstract][Full Text] [Related]
2. Liquid Biopsies for Neuroendocrine Tumors: Circulating Tumor Cells, DNA, and MicroRNAs.
Rizzo FM; Meyer T
Endocrinol Metab Clin North Am; 2018 Sep; 47(3):471-483. PubMed ID: 30098711
[TBL] [Abstract][Full Text] [Related]
3. [Advances of circulating biomarkers in gastroenteropancreatic neuroendocrine neoplasms].
Chen L; Chen M; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Mar; 20(3):357-360. PubMed ID: 28338171
[TBL] [Abstract][Full Text] [Related]
4. Are Markers of Systemic Inflammatory Response Useful in the Management of Patients With Neuroendocrine Neoplasms?
Giannetta E; La Salvia A; Rizza L; Muscogiuri G; Campione S; Pozza C; Colao AAL; Faggiano A
Front Endocrinol (Lausanne); 2021; 12():672499. PubMed ID: 34367064
[TBL] [Abstract][Full Text] [Related]
5. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame.
Marotta V; Zatelli MC; Sciammarella C; Ambrosio MR; Bondanelli M; Colao A; Faggiano A
Endocr Relat Cancer; 2018 Jan; 25(1):R11-R29. PubMed ID: 29066503
[TBL] [Abstract][Full Text] [Related]
6. Consensus on biomarkers for neuroendocrine tumour disease.
Oberg K; Modlin IM; De Herder W; Pavel M; Klimstra D; Frilling A; Metz DC; Heaney A; Kwekkeboom D; Strosberg J; Meyer T; Moss SF; Washington K; Wolin E; Liu E; Goldenring J
Lancet Oncol; 2015 Sep; 16(9):e435-e446. PubMed ID: 26370353
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine tumor biomarkers: From monoanalytes to transcripts and algorithms.
Modlin IM; Bodei L; Kidd M
Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):59-77. PubMed ID: 26971844
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers.
Herrera-Martínez AD; Hofland LJ; Gálvez Moreno MA; Castaño JP; de Herder WW; Feelders RA
Endocr Relat Cancer; 2019 Mar; 26(3):R157-R179. PubMed ID: 30615596
[TBL] [Abstract][Full Text] [Related]
9. Are circulating tumor cells a new, valid prognostic marker in neuroendocrine tumors?
Antonuzzo L; Meoni G; Di Costanzo F
J Clin Oncol; 2013 Jul; 31(19):2518. PubMed ID: 23715563
[No Abstract] [Full Text] [Related]
10. Circulating Cancer Biomarkers: The Macro-revolution of the Micro-RNA.
Montani F; Bianchi F
EBioMedicine; 2016 Mar; 5():4-6. PubMed ID: 27077096
[TBL] [Abstract][Full Text] [Related]
11. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer.
Madhavan D; Zucknick M; Wallwiener M; Cuk K; Modugno C; Scharpff M; Schott S; Heil J; Turchinovich A; Yang R; Benner A; Riethdorf S; Trumpp A; Sohn C; Pantel K; Schneeweiss A; Burwinkel B
Clin Cancer Res; 2012 Nov; 18(21):5972-82. PubMed ID: 22952344
[TBL] [Abstract][Full Text] [Related]
12. The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut.
Ardill JE; Erikkson B
Endocr Relat Cancer; 2003 Dec; 10(4):459-62. PubMed ID: 14713258
[TBL] [Abstract][Full Text] [Related]
13. Circulating Biomarkers for Prediction of Treatment Response.
Cappelletti V; Appierto V; Tiberio P; Fina E; Callari M; Daidone MG
J Natl Cancer Inst Monogr; 2015 May; 2015(51):60-3. PubMed ID: 26063889
[TBL] [Abstract][Full Text] [Related]
14. Profiling cell-free and circulating miRNA: a clinical diagnostic tool for different cancers.
Chakraborty C; Das S
Tumour Biol; 2016 May; 37(5):5705-14. PubMed ID: 26831657
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors of response to mTOR inhibitors in neuroendocrine tumours.
Zatelli MC; Fanciulli G; Malandrino P; Ramundo V; Faggiano A; Colao A;
Endocr Relat Cancer; 2016 Mar; 23(3):R173-83. PubMed ID: 26666705
[TBL] [Abstract][Full Text] [Related]
16. Micromarkers 2.0: an update on the role of microRNAs in cancer diagnosis and prognosis.
Ferracin M; Negrini M
Expert Rev Mol Diagn; 2015; 15(10):1369-81. PubMed ID: 26338209
[TBL] [Abstract][Full Text] [Related]
17. Circulating microRNAs as diagnostic and prognostic tools for hepatocellular carcinoma.
Zhang YC; Xu Z; Zhang TF; Wang YL
World J Gastroenterol; 2015 Sep; 21(34):9853-62. PubMed ID: 26379392
[TBL] [Abstract][Full Text] [Related]
18. Neuropilin 2 and soluble neuropilin 2 in neuroendocrine neoplasms.
Gerard L; Patte C; Chardon L; Hervieu V; Payen L; Allio M; Marx C; Clermidy H; Durand A; Mehlen P; Bollard J; Poncet G; Roche C; Gibert B; Walter T
Endocr Relat Cancer; 2024 Jun; 31(6):. PubMed ID: 38642579
[TBL] [Abstract][Full Text] [Related]
19. Clinical relevance of circulating cell-free microRNAs in cancer.
Schwarzenbach H; Nishida N; Calin GA; Pantel K
Nat Rev Clin Oncol; 2014 Mar; 11(3):145-56. PubMed ID: 24492836
[TBL] [Abstract][Full Text] [Related]
20. Reply to L.Antonuzzo et al.
Meyer T; Khan MS
J Clin Oncol; 2013 Jul; 31(19):2519. PubMed ID: 23967492
[No Abstract] [Full Text] [Related]
[Next] [New Search]
